Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$LEXX posted on Stockhouse by Iscfa.
https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_01222024_LEXX_Vandermosten.pdf
I bought some too. Looks like much of the sell of is shorts. Available short shares wentfrom 250,000 to 100,000
Got in on this mornings dip, quite the gift.
All the best,
Knife
Trade 2 million shares today? Heavy buying after the flippers are out
Nothing but good news, let's see if this puppy can close up today!!
Buying here and now! This is a gift
Anyone else just buy this premarket dip? I am gonna hope that this isnt foreshadowing, but more so cleaning out the pipes before releasing news. We shall see...but it barely moved my average. Still very green.
Lots like a 'Sell-on-news event' down .75 on pre-market.
$LEXX, Oprah on the Today Show just now. All about weight loss drugs working , where Weight watchers did not. Next leg up!!!
Thanks Shawking - eom
Thanks Shawking - eom
Ted Ohashi, in response to comments about a possible 'sell-on-news event'.
"Just so you know. I am just concluding some research that indicates the LEXX rally may be less to do with the IND application and more to do with the GLP-1 potential for diabetes/obesity. This sector is white hot in the states. You know from what I've been saying in the Let's Toke Business newsletter that the IND application is very important to me and I have also been thinking about a "sell on history" response but it looks like there are a couple of drivers and from a US market point of view, the GLP-1 might be even more important. I'm just looking at a few more items to solidify my conclusion. In other words there may not be a "sell on history" correction."
Another raise coming? Lolz
Waiting for $20, it's true value just based on IP and product pipelines
Or ran into it. LOL
Wow! Just smashed through the 3 dollar level!
The sp is certainly weathering the capital raise news much better than the last time. Feels good.
I am.telling u , this one can go $20/- in one day,
KALA went from $3.50 to $56 in 3 days on IND approval
and that now gives them an $8.5 Billion Market Cap!! Last Oct. they were at $10 now $85!
Viking jumped $47/share today on good results for their weight loss drug. Just goes to show you what could happen. Viking has 100 million O/S
https://finance.yahoo.com/news/viking-therapeutics-announces-positive-top-120300339.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuYmluZy5jb20v&guce_referrer_sig=AQAAALu4MpX6Qn2BSlj9waa7q14hC7Otmez8qlm-Fj9RkUHJ2bDhtAjVVg6KmYpQPs3dKxgN2E9fN1XO6HtL2h_uW0Q1ncqz0gS7tJ_R9CPcapIIcEBre6K2-rfs01odYyfL5wF3wRKnMbvZdyuQG3-n9PyKWu86rcGlyAysf7IEuOWb
Let's hope we don't sell off. We need to stay above$2.32 to stay in a bullish chart comparison that I'm watching.
Buying has returned. Exciting times.
Special Report: Lexaria announces and closes US$3.6 million equity offering…………….....…….....p 5
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_8b1ee2344c7449f7b0678bad1d9d6293.pdf
A new drug and a new procedure for hypertension.
https://www.msn.com/en-us/health/other/new-procedure-is-game-changing-for-patients-with-high-blood-pressure-doctors-say/ar-AA1m4PGv
https://www.healthline.com/health-news/single-injection-of-drug-zilebesiran-lowers-blood-pressure-for-6-months#:~:text=1%20A%20new%20drug%20called%20zilebesiran%20may%20help,day%2C%20and%20many%20people%20struggle%20with%20the%20regimen.
Looks like management is getting ready to give themselves another raise!
All Institutional ownership results by the end of Dec '23 add up to just less than 11%!! Insiders own 6%. Things have obviously changed in the last 6 weeks but haven't seen anyone claiming a new 13D - 5% ownership filing this year!
https://www.nasdaq.com/market-activity/stocks/lexx/institutional-holdings
Maybe they got accepted and just haven't released it yet. They can't start the trials until 30 days after the application but it doesn't mean the FDA needs that whole 30 days to evaluate the application! I see the acceptance being issued very soon! - I think LEXX wouldn't raise the $ if they weren't sure they needed it!
I have mixed feelings. The skeptic in me says....why now? Why not wait until after the news to see the best return, and less shares issued. The optimist in me thinks what you said. Expecting/Knowing favorable results...so get the money on the books now so that everything is line up and ready to go to hit the ground running.
With that being said, I did buy a little more this morning...and if it gets close to $2 will add again.
Nice move. Clinical trials, here we come!!
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Kelowna, British Columbia – February 15, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has entered into definitive agreements for the purchase and sale of 1,558,443 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.31 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 1,558,443 shares of common stock at an exercise price of $2.185 per share that will be immediately exercisable upon issuance and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about February 16, 2024, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be approximately $3.6 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for research and development studies and the patent and legal costs associated thereto, and for general working capital purposes.
The common stock (or common stock equivalents) (but not the unregistered warrants and the shares of common stock underlying the unregistered warrants) described above are being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-262402) that was declared effective by the Securities and Exchange Commission (the “SEC”) on February 4, 2022. The offering of the shares of common stock (or common stock equivalents) is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
The unregistered warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying such unregistered warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the unregistered warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
https://www.marketscreener.com/quote/stock/LEXARIA-BIOSCIENCE-CORP-25530934/news/Lexaria-Announces-3-6-Million-Registered-Direct-Offering-Priced-At-The-Market-Under-Nasdaq-Rules-45962079/
The gross proceeds to the Company from the offering are expected to be approximately $3.6 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for research and development studies and the patent and legal costs associated thereto, and for general working capital purposes.
Wayne Boos reporting 480,000 shares owned at EOY - up 30,000 from Sept 30, '23.
https://ir.lexariabioscience.com/sec-filings/all-sec-filings##document-1915-0001235126-24-000010-2
(a) As of December 31, 2023, Wayne W. Boos beneficially owns
a total of 480,000 shares of the Companys Common Stock which
represent approximately 4.67078% of the outstanding Common Stock,
based on 10,276,641 Common Stock outstanding as of November 20, 2023,
as indicated by the Company. The percentage of Mr. Boos ownership of
Common Stock in the Company has varied since the filing of this
Schedule 13D as Mr. Boos has (i) purchased additional shares of the
Companys Common Stock, (ii) he has sold shares of the Companys
Common Stock, and (iii) the Company has issued additional shares of
Common Stock.
(b) Nature of Ownership. Wayne W. Boos has the sole power to
vote and direct the disposition of all of the 480,000 shares
reported as beneficially owned by him.
(c) Recent Transactions. In the 60 days prior to
December 31, 2023, Wayne W. Boos (i) sold 30,000 shares of the
Companys Common Stock for an average price per share of $1.31
and (ii) acquired 90,000 shares of the Companys Common Stock
for an average price per share of $1.405597 through his broker,
Merrill Lynch.
(d)No other person has the right to receive or the power to
direct the receipt of the dividends from, or proceeds from the
sale of, such securities.
(e) Wayne W. Boos ceased to be the beneficial owner of more than
five percent of the Companys Common Stock on or about
October 3, 2023, when the Company issued additional
shares of the Companys Common Stock.
No predictions since the odds of being correct are pretty small, but take the market cap now 27 million and divide the future market cap you expect by 27 million. Multiply that by the current share price and you have a ball park price prediction. You can also overlay that guess on technical data for historical prices for resistance and support. For any period of euphoria or panic, I have typically seen market caps (in any sector) temporarily go way above or way below my guesses. Of course, I am hoping for way above here.
BTW I have a few lots at $36 and $26, along with a few hundred from 0.70 to 4.50
Comparing #KALA, and it's IND approval
2nd $78 is all.time high.so if the tech is good, then lending 10-20 mil for trials will be the simple bet that anybbig pharma can afford, and they don't have shell $1.8 bil like Novo Nordisk
This could be a breakout year and a multi bagger stock this year
I never thought bumka would be diluting shit out of existing shareholders, and nicotine.deal will provide for biotech r&d
That's pretty ambitious. How do you get those numbers? I'm not complaining. If it got to $78 I might party for a year straight!
THANK YOU everyone for your posts--GLTA
Expecting $25-$30 on IND approval and settling at about $12-14 for long term for 2024. I won't be surprised if $78/- get's tested in 2024 on Pharma /Tobacco partnership news
Invenomic just declaring 731,000 shares by EOY. This is down 34,000 ish from end of Sept. last year. Who knows what they've done form the EOY to now?
https://ir.lexariabioscience.com/sec-filings/all-sec-filings##document-1914-0001214659-24-002623-2
LEXARIA BIOSCIENCE CORP.
Filed by
INVENOMIC CAPITAL MANAGEMENT LP
Telephone CIK Symbol SIC Code Industry Sector Fiscal Year
FORM SC 13G/A
(Amended Statement of Ownership)
Filed 02/14/24
https://www.otcmarkets.com/filing/conv_pdf?id=17271961&guid=AJd-kaQlROwfJth
Also curious about where Invenomic now stands as they are the biggest shareholder!
Make sure that they are GTC orders though.
https://fintel.io/ss/us/lexx
I have never seen the short borrow fees this high! Anyone who has not put sell orders in should, even if you put them at $100. What that does is keeps the brokers from shorting the shares that you own and also making it more expensive to short.
I've been watching for that too. I see Armistice has sold all their 890,000 shares before the end of last year. I don't see Wayne Boos (who already declared 5%) declaring more yet. I also see a new Institutional owner: Cowen and Co, with just over 250,000 by the end of last year but still waiting on Vanguard and Boothbay to release their most recent amounts to the end of '23.
But....a lot has happened since then. I'm thinking whoever is buying up shares is also selling down at the same time or else they would be filing their 13D unless there's lots of big buyers? Hard to know!
I need a lot more than $2.50 a share to just break even --
Followers
|
221
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
34612
|
Created
|
10/02/07
|
Type
|
Free
|
Moderators |
Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules. By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.
Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners
Effects are felt within 15-20 min vs. 60-120 min.
Initial testing indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects and reducing liver biotransformation.
Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.
Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) drug payloads. It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:
Lexaria Bioscience Corp. (“Lexaria”) has formed the Lexaria Nicotine Corp. as its exclusive worldwide nicotine business unit. More than 89% of all nicotine that is consumed worldwide is delivered through smoking cigarettes. Approximately 6,000,000 deaths per year around the world are attributed primarily to the delivery of nicotine through the act of smoking according to the Centers for Disease Control and Prevention. Of note: “…it is primarily the toxins and carcinogens in tobacco smoke – not the nicotine – that cause illness and death.” (U.K. National Institute for Health and Care Excellence [NICE]). As many as 69% of U.S. adult smokers want to quit smoking and 43% of US adult smokers have attempted to quit in any twelve-month period. Lexaria postulates that delivery of nicotine to satisfy current demand, utilizing our patented DehydraTECH technology in common food and consumer product formats, could shift demand away from smoking cigarettes. However, ingestion of nicotine is challenging because it is poorly tolerated by the human gastrointestinal system and then significantly metabolized by the liver, thereby diminishing its overall effectiveness through edibles. Lexaria’s DehydraTECH technology offers a means to formulate ingestible product formats of nicotine and/or its analogs with higher bioavailability performance possibilities due to the benefits of our technology.
Lexaria is developing a patent suite with supporting intellectual property in the pharmaceutical sector that will supply significant long-term strategic growth potential. Lexaria Pharmaceutical Corp. is the 100%-owned subsidiary that has obtained exclusive worldwide rights to Lexaria’s patent portfolio related to pharmaceutical applications. Currently within this business unit resides the IP for Non-Steroidal Anti-Inflammatories (NSAIDs), Vitamins, hormone treatments utilizing estrogen or testosterone, phosphodiesterase inhibitors (PDE5). Additional molecules of interest could be added to this unit over time.
According to Statista.com, the global pharma industry was worth $1,105 billion in 2016, and the US pharma industry alone spent over $71 billion in 2017 on R&D: a larger R&D expenditure than the entire gross revenues of many other business sectors.. Lexaria Pharmaceutical Corp. is implementing a strategy of reinforcing its IP-suite to sufficient degree to begin partnering within this dynamic industry.
The Lexaria Hemp Co. holds exclusive global rights to the Lexaria patent portfolio related to hemp-based applications. Lexaria’s DehydraTECH technology is designed to deliver functional ingredients within hemp in oral product formats with significantly enhanced palatability, speed of effectiveness and potency as a viable and healthier alternative to conventional inhalational (i.e. smoking or vaping) administration practices. Extensively evaluated through invivo, invitro, and human clinical studies, one of the most extensive databases in the world has been collected by Lexaria related to hemp-based ingredients empowered with our DehydraTECH technology. In 2018, the World Anti Doping Agency (WADA) for the first time ever exempted cannabidiol from hemp from its list of restricted substances on its International Standards Prohibited List of substances.
Lexaria CanPharm Corp, a Canadian corporation, owns exclusive global rights to Lexaria’s intellectual property as it is applied to psychotropic bioactive molecules that act upon human CB1 and CB2 receptors in those areas of the world where it is permissible to do so. Substances that act upon these receptors and systems in the human body that affect pain, inflammation, anxiety and depression, and have also been shown to have utility against cancer and neurodegenerative conditions. Lexaria’s ground-breaking 2018 research that proved many-fold improvements in delivering an active ingredient across the blood-brain-barrier could have disruptive potential within this business sector as well as all others where Lexaria is active.
The safety and effectiveness of Lexaria’s DehydraTECH™ technology has been studied in a series of controlled and well designed in vitro and in vivo human focus studies, examining factors such as total bioabsorption directly and indirectly through surrogate biomarkers, time to onset of effectiveness, flavor appeal and quality of effectiveness. Studies to-date have focused on cannabinoid applications where Lexaria is most advanced commercially, although research is underway for the other bioactive compounds named in Lexaria’s patent portfolio and described under Commercial Applications.
Pre-Clinical Research into Lexaria’s DehydraTECH™
An in vitro absorption study was performed to assess unidirectional CBD permeability using a human epi-intestinal tissue model with various formulations in the presence of simulated intestinal fluid. The study was designed to, as closely as possible, mimic intestinal absorption as it would occur in a live subject. Samples of Lexaria’s commercially available CBD-fortified ViPova™ black tea were administered in the model compared with concentration-matched CBD control preparations that lacked Lexaria’s patented formulation and process enhancements. The study showed as much as a 499% improvement, on average, in intestinal tissue permeability with the ViPova™ black tea formulation relative to a concentration-matched CBD control preparation without any Lexaria technology enhancements. The study also showed a 325% improvement, on average, in intestinal tissue permeability comparing the ViPova™ black tea preparation to a concentration-matched CBD control preparation that utilized Lexaria`s dehydration synthesis processing methodology but lacked its fatty acid ingredient incorporation, demonstrating the power of the Lexaria technology as a whole (see Figure 1).
Following this study, a series of independent, well designed, well controlled human focus studies were undertaken corroborating Lexaria’s in vitro performance findings. A study in healthy volunteers (n=6) suggested as much as a 5-10X increase in CBD absorption, which was assessed indirectly through measurement of the increase in salivary nitric oxide as a directly proportional surrogate biomarker, with onset of action in as little as 15-30 minutes. In all cases, the maximum increased level of salivary nitric oxide remained evident at the 60-minute end period of this particular test. Further testing is required to determine the full duration of elevated nitric oxide levels.
Thereafter, a blinded human focus study was conducted to evaluate the performance of THC-infused chocolates formulated using Lexaria’s DehydraTECH™ technology. This study compared the performance of the THC-infused chocolates powered by Lexaria’s technology to concentration matched THC-infused chocolates formulated using a commercial dextrin absorption enhancer. The subjects (n=12) that participated in this study indicated a clear preference on taste and overall effectiveness with the chocolates formulated using Lexaria’s technology, and onset of effectiveness was again observed very quickly, in as little as 15-20 minutes.
Lexaria Bioscience Corp’s disruptive new patented technology DehydraTECH™ is available to be licensed.
DehydraTECH can be used to improve existing products or to create new products. It is suitable for use with a wide range of consumer product formats including:
DehydraTECH is designed to be effective in delivering most fat-soluble molecules through the human gastrointestinal system and has also demonstrated affinity for transdermal applications and even effectiveness in crossing the blood-brain-barrier once within blood plasma. Lexaria has, or is conducting, in vitro, in vivo and human clinical testing, including pharmacokinetic data gathering, for the delivery of API’s through ingestible means. Test data has consistently pointed to reduced time required to enter the bloodstream, increased absorption rate, and reported improvements in taste and smell of edible products.
Contact us today to speak about your licensing needs at ablanchard@lexariabioscience.com
Terms and rights associated with our licensing opportunities are discussed on an individual basis.
Lexaria’s typical approach to working with a new prospective licensee is to effect confidentiality terms and then collaborate with the license prospect under a non-binding letter of intent to evaluate the feasibility and applicability of the Lexaria DehydraTECH technology for the license prospect`s needs. Following this, if the license prospect is satisfied with the performance enhancements delivered by the DehydraTECH technology, Lexaria then seeks to transition to a definitive fee bearing agreement structure between it and the new licensee.
We will license our technology in any of the more than 40 countries around the world where the DehydraTECH is patented or patent-pending. Licensees can feel confident that Lexaria’s extensive IP portfolio – constantly expanding – will help to provide a competitive edge and protection against inferior methodologies or older, outdated technology.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Licensees should also always remember that DehydraTECH costs less than a penny per serving to implement – sometimes a bare fraction of a penny. Licensees may experience an increase in market share or an increase in pricing power as a result of offering their customers superior delivery characteristics. Customers are loyal to the improved performance of DehydraTECH based products.
DehydraTECH is one of the world’s ONLY delivery technologies that does not require the addition of chemicals or intimidating, complex ingredients requiring disclosure on a food label. DehydraTECH works with commons GRAS ingredients that can be organic, gluten-free, and dairy free.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Masks taste/odor
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners.
Reduces time of onset
Effects are felt within 15-20 min vs. 60-120 min.
Increases bio-absorption
Increases bio-absorption by 2 – 10x, to equate or exceed that of other routes of administration like inhalational delivery.
Avoids first-pass liver metabolism
Testing has evidenced that DehydraTECH may deliver molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects. More recent testing in animals even demonstrated an ability to cross the blood-brain-barrier to a degree previously thought not possible.
Interview with CEO Chris Bunka
https://youtu.be/9bRSWYKIEL8
New Enhanced DehydraTECHTM formulation delivers 8X more CBD into blood and over 19X more CBD into brain tissue than standard industry formulations.
Kelowna, British Columbia – June 4, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, has discovered improved performance characteristics of a new version of the DehydraTECHTM delivery platform initially suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical, and supplement markets. Lexaria’s innovative use of a naturally sourced formulation enhancement more than doubles DehydraTECH’s absorption performance compared to previous DehydraTECH results demonstrated to-date. The Company has filed new patent applications related to the recent innovations.
BACKGROUND
On March 20, 2019 Lexaria announced it was beginning a series of animal studies with multiple objectives, including evaluating enhanced DehydraTECH formulations that might offer improved performance. Copious data streams have been generated from these tests and continue to be analyzed.
In this arm of animal study, Lexaria tested its DehydraTECH delivery technology with compounds postulated to behave in a synergistic fashion for enhancement of gastro-intestinal absorption, which resulted in significantly enhanced DehydraTECH performance (“Enhanced DehydraTECH”).
Of note, the new Enhanced DehydraTECH and its improved performance is separate and distinct from the nanotech improvement techniques recently announced by the Company.
TEST RESULTS
In each arm of the Lexaria animal studies, 10 male Sprague-Dawley rats were administered an identically sourced CBD at a rate of 25mg per kg of bodyweight. Delivery of CBD into the bloodstream was measured at 2; 4; 6; 8; 12; 15; 30; 45; and 60 minutes after dosing. DehydraTECH-enabled CBD was measurable in animal blood within 2 to 4 minutes after dosing.
On May 15, 2019 the Company reported that DehydraTECH achieved a CBD blood concentration level that was 475% more than a generic industry medium chain triglyceride (“MCT”) coconut-oil formulation 15 minutes after dosing. Today, the Company reports that Enhanced DehydraTECH led to 811% more CBD delivery into blood than generic industry MCT coconut-oil formulations (p=0.00008); and 110% more CBD into blood than DehydraTECH in its traditional format (p=0.02).
Also of note is that both traditional DehydraTECH and Enhanced DehyraTECH delivered maximum blood concentration levels prior to the 60-minute end-of-test, with levels tapering off thereafter. The DehydraTECH technology therefore demonstrates both fast onset and fast offset as tested which is of interest for dose titration purposes when repeated dosing is desired.
CONCLUSION
DehydraTECH’s in its traditional format has been used commercially by the Company since 2014; and by the Company’s technology licensees since 2016. Lexaria has consistently introduced leading innovation for oral cannabis formats such as capsules, beverages and edibles, with a focus on the consumer experience as measured by qualities such as taste, rapidity of onset and offset, and reliability of effect. Unique among the cannabis industry, DehydraTECH has proven itself equally transformative in other sectors such as the nicotine industry where Lexaria has licensed its technology to one of the largest nicotine products companies in the world.
Enhanced DehydraTECH seems particularly adept at delivering previously unreachable quantities of CBD across the blood brain barrier and into brain tissue; more so than even the most advanced nanotech as previously reported utilized in these studies. Since most human receptor cells of the CB1 variety and otherwise that are associated with the psychotropic effects of cannabinoids are located within the brain these findings significantly expand upon the power of Lexaria’s technology to reach the target site of action for these purposes.
With this new innovation, Lexaria is establishing new performance thresholds for drug delivery technology, with tested performance of 8x (blood plasma) and more than 19x (brain tissue) of generic industry formulations. The Company intends to perform further studies to fully characterize Enhanced DehydraTECH and will work throughout 2019 to optimize implementation into the best product applications for use by its licensees.
The animal test results announced to date have led to additional new patent applications based on the positive performance results achieved. The specific nature of enhanced DehydraTECH shall remain undisclosed for proprietary reasons until the new patent filings are published. Although the current tests were limited to CBD absorption, Lexaria expects knowledge from the current innovation to apply equally to tetrahydrocannabinol (THC) as well to enhance formulation innovation for nicotine and various pharmaceutical compounds already named within the Lexaria patent suite.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |